Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Voorraadrapport

Marktkapitalisatie: US$327.9m

Aclaris Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Aclaris Therapeutics is Neal Walker, benoemd in Jul2012, heeft een ambtstermijn van 12.33 jaar. bezit rechtstreeks 1.93% van de aandelen van het bedrijf, ter waarde $ 6.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 10.5 jaar.

Belangrijke informatie

Neal Walker

Algemeen directeur

US$73.5k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO12.3yrs
Eigendom CEO1.9%
Management gemiddelde ambtstermijn2.4yrs
Gemiddelde ambtstermijn bestuur10.5yrs

Recente managementupdates

Recent updates

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Analyse CEO-vergoeding

Hoe is Neal Walker's beloning veranderd ten opzichte van Aclaris Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$4mUS$550k

-US$82m

Sep 30 2018n/an/a

-US$81m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$86m

Dec 31 2017US$810kUS$510k

-US$50m

Compensatie versus markt: De totale vergoeding ($USD 73.50K ) Neal } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).

Compensatie versus inkomsten: De vergoeding van Neal is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Neal Walker (54 yo)

12.3yrs

Tenure

US$73,500

Compensatie

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Neal Walker
Co-Founder12.3yrsUS$73.50k1.93%
$ 6.3m
Kevin Balthaser
Chief Financial Officer1.8yrsUS$2.34m0.035%
$ 113.3k
Joseph Monahan
Chief Scientific Officer3.8yrsUS$2.26m0.26%
$ 858.2k
James Loerop
Chief Business Officer2.8yrsUS$2.33m0.048%
$ 156.1k
Matthew Rothman
General Counsel & Corporate Secretary2.4yrsgeen gegevensgeen gegevens
Jon Jacobsen
Senior Vice President of Chemistryno datageen gegevensgeen gegevens
Steve Tucker
Senior Vice President of Project Leadershipless than a yeargeen gegevensgeen gegevens
Ajay Aggarwal
Senior Vice President of Clinical Developmentless than a yeargeen gegevensgeen gegevens

2.4yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ACRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Neal Walker
Co-Founder12.3yrsUS$73.50k1.93%
$ 6.3m
Vincent Milano
Independent Director4.8yrsUS$180.38k0.018%
$ 57.5k
Mark Bradshaw
Member of Advisory Boardno datageen gegevensgeen gegevens
James Leyden
Member of Advisory Boardno datageen gegevensgeen gegevens
Klaus Theobald
Member of Advisory Boardno datageen gegevensgeen gegevens
Anand Mehra
Independent Director10.2yrsUS$194.38k0.061%
$ 199.0k
Pearl Grimes
Member of Advisory Boardno datageen gegevensgeen gegevens
Guy Webster
Member of Advisory Boardno datageen gegevensgeen gegevens
Christopher Molineaux
Lead Independent Director10.8yrsUS$206.88k0.074%
$ 244.0k
Kenneth Beer
Member of Advisory Boardno datageen gegevensgeen gegevens
Leslie Baumann
Member of Advisory Boardno datageen gegevensgeen gegevens
Andrew Ondo
Member of Advisory Boardno datageen gegevensgeen gegevens

10.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACRS zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.5 jaar).